公开(公告)号：EP1720575B1

公开(公告)日：2015-05-20

申请号：EP05726492.1

申请日：2005-02-11

申请人： Immunomedics Inc.

发明人： MCBRIDE, William J. ,  GOLDENBERG, David, M. ,  NOREN, Carl ,  HANSEN, Hans, J.

IPC分类号： A61K39/395 ,  A61K51/00 ,  A01N37/02 ,  C07C69/74 ,  A61P35/00

CPC分类号： A61K51/0497 ,  A61K47/665 ,  A61K51/04 ,  A61K51/0455 ,  A61K51/048 ,  A61K51/1048 ,  A61K51/1063 ,  A61K2039/505 ,  B82Y5/00 ,  C07K5/06078 ,  C07K5/1013 ,  C07K5/1016 ,  C07K5/1019 ,  C07K7/06 ,  C07K16/18 ,  C07K16/3007 ,  C07K16/3046 ,  C07K16/44 ,  C07K16/468 ,  C07K2317/12 ,  C07K2317/13 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2319/00

公开(公告)号：EP1519959B1

公开(公告)日：2014-04-02

申请号：EP03706703.0

申请日：2003-02-14

申请人： Immunomedics, Inc.

发明人： HANSEN, Hans ,  QU, Zhengxing ,  GOLDENBERG, David, M.

IPC分类号： C07K16/28 ,  A61K39/395 ,  C12N15/13 ,  C12N5/10 ,  G01N33/53

CPC分类号： C07K16/2803 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/2887 ,  C07K2317/24 ,  C07K2317/56

公开(公告)号：EP2552483A1

公开(公告)日：2013-02-06

申请号：EP11763313.1

申请日：2011-03-29

申请人： Immunomedics, Inc.

发明人： CHANG, Chien-Hsing ,  GOLDENBERG, David, M.

IPC分类号： A61K39/395

CPC分类号： C07K16/2833 ,  A61K31/4965 ,  A61K47/484 ,  A61K47/48423 ,  A61K47/4843 ,  A61K47/6807 ,  A61K47/6813 ,  A61K47/6815 ,  A61K47/6849 ,  A61K47/6881 ,  A61K47/6885 ,  C07K16/18 ,  C07K16/2803 ,  C07K16/2851 ,  C07K16/2863 ,  C07K16/2887 ,  C07K16/30 ,  C07K16/3007 ,  C07K16/3092 ,  C07K16/44 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/35 ,  C07K2317/51 ,  C07K2317/52 ,  C07K2317/522 ,  C07K2317/55 ,  C07K2317/73 ,  C07K2317/734 ,  C07K2317/75 ,  C07K2317/77 ,  C07K2319/70 ,  C12N15/113 ,  C12N2310/14 ,  C12N2310/3513 ,  C12N2320/32 ,  Y02A50/403

摘要： Disclosed herein are methods and compositions comprising anti-CD74 and/or anti-HLA-DR antibodies for treatment of GVHD and other immune dysfunction diseases. In preferred embodiments, the anti-CD74 and/or anti-HLA-DR antibodies are effective to deplete antigen-presenting cells, such as dendritic cells. Most preferably, administration of the therapeutic compositions depletes all subsets of APCs, including mDCs, pDCs, B cells and monocytes, without significant depletion of T cells. In alternative embodiments, administration of the therapeutic compositions suppresses proliferation of allo-reactive T cells, while preserving cytomegalovirus (CMV)-specific, CD8+ memory T cells. The compositions and methods provide a novel conditioning regimen for preventing aGVHD and/or treating chronic GVHD, without altering preexisting anti-viral immunity.

摘要翻译： 本文公开了用于治疗GVHD和其他免疫功能障碍疾病的包含抗CD74和/或抗HLA-DR抗体的方法和组合物。 在优选的实施方案中，抗CD74和/或抗HLA-DR抗体有效消除抗原呈递细胞如树突细胞。 最优选地，治疗组合物的施用耗尽了APC的所有子集，包括mDC，pDC，B细胞和单核细胞，而没有显着耗尽T细胞。 在替代实施方案中，治疗组合物的施用抑制同种异体反应性T细胞的增殖，同时保留巨细胞病毒（CMV）特异性CD8 +记忆T细胞。 该组合物和方法提供了用于预防aGVHD和/或治疗慢性GVHD的新型预处理方案，而不改变预先存在的抗病毒免疫性。

公开(公告)号：EP1587550B1

公开(公告)日：2011-07-27

申请号：EP04737253.7

申请日：2004-02-02

申请人： Immunomedics, Inc.

发明人： MCBRIDE, William ,  HANSEN, Hans, J. ,  CHANG, Chien-Hsing, Ken ,  GOLDENBERG, David, M.

IPC分类号： A61K51/08

CPC分类号： B82Y5/00 ,  A61K47/6891 ,  Y10S435/975

摘要： Methods and compositions are described for targeting therapeutic and diagnostic molecules to particular types of cells using targeting antibodies or other targeting moeities.

公开(公告)号：EP1483294B1

公开(公告)日：2010-08-11

申请号：EP03743421.4

申请日：2003-03-03

申请人： Immunomedics, Inc.

发明人： HANSEN, Hans ,  LEUNG, Shui-on, 10c, University Residence ,  QU, Zhengxing ,  GOLDENBERG, David, M.

IPC分类号： C07K16/28 ,  A61K39/395 ,  A61P35/02 ,  G01N33/574

CPC分类号： A61K45/06 ,  A61K38/00 ,  A61K47/6849 ,  A61K51/1027 ,  A61K2039/505 ,  C07K16/2833 ,  C07K16/2896 ,  C07K2317/24 ,  C07K2317/77

摘要： The present invention provides humanized, chimeric and human anti-CD74 antibodies, CD74 antibody fusion proteins, immunoconjugates, vaccines and bispecific that bind to CD74, the major histocompatibility complex (MHC) class-II invariant chain, Ii, which is useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignancies, other malignancies in which the cells are reactive with CD74, and autoimmune diseases, and methods of treatment and diagnosis.

公开(公告)号：EP0969866B2

公开(公告)日：2009-02-18

申请号：EP98912936.6

申请日：1998-03-17

申请人： Immunomedics, Inc.

发明人： GOLDENBERG, David, M.

IPC分类号： A61K39/395 ,  A61K31/00 ,  A61K38/19

CPC分类号： C07K16/2803 ,  A61K38/00 ,  A61K39/39558 ,  A61K2039/505 ,  A61K2300/00

摘要： B-Cell malignacies, such as the B-cell subtype of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, are significant contributors to cancer mortality. The response of B-cell malignancies to various forms of treatment is mixed. Traditional methods of treating B-cell malignancies, including chemotherapy and radiotherapy, have limited utility due to toxic side effects. Immunotherapy with anti-CD20 antibodies have also provided limited success. The use of antibodies that bind with the CD22 antigen, however, provides an effective means to treat B-cell malignancies such as indolent and aggressive forms of B-cell lymphomas, and acute and chronic forms of lymphatic leukemias. Moreover, immunotherapy with anti-CD22 antibodies requires comparatively low doses of antibody protein, and can be used effectively in multimodal therapies.

公开(公告)号：EP1720575A2

公开(公告)日：2006-11-15

申请号：EP05726492.1

申请日：2005-02-11

申请人： Immunomedics Inc.

发明人： MCBRIDE, William J. ,  GOLDENBERG, David, M. ,  NOREN, Carl ,  HANSEN, Hans, J.

IPC分类号： A61K39/395

CPC分类号： A61K51/0497 ,  A61K47/665 ,  A61K51/04 ,  A61K51/0455 ,  A61K51/048 ,  A61K51/1048 ,  A61K51/1063 ,  A61K2039/505 ,  B82Y5/00 ,  C07K5/06078 ,  C07K5/1013 ,  C07K5/1016 ,  C07K5/1019 ,  C07K7/06 ,  C07K16/18 ,  C07K16/3007 ,  C07K16/3046 ,  C07K16/44 ,  C07K16/468 ,  C07K2317/12 ,  C07K2317/13 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2319/00

摘要： Disclosed are compounds that include two or more haptens conjugated by a spacer or a carrier. The haptens may include diethylenetriaminepentaacetate (DTPA), histimine-succinyl-glutamine (HSG), or combinations of DTPA and HSG. The compound also includes an effector molecule which may be conjugated to one or more of the haptens, the spacer/carrier, or both. The effector molecule may be conjugated by a number of linkages including an ester linkage, an imino linkage, an amino linkage, a sulfide linkage, a thiosemicarbazone linkage, a semicarbazone linkage, an oxime linkage, an ether linkage, or combinations of these linkages. Also disclosed are methods of synthesizing the compounds and/or precursors of the compounds.

公开(公告)号：EP1519959A2

公开(公告)日：2005-04-06

申请号：EP03706703.0

申请日：2003-02-14

申请人： Immunomedics, Inc.

发明人： HANSEN, Hans ,  QU, Zhengxing ,  GOLDENBERG, David, M.

IPC分类号： C07K16/28 ,  A61K39/395 ,  C12N15/13 ,  C12N5/10 ,  G01N33/53

CPC分类号： C07K16/2803 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/2887 ,  C07K2317/24 ,  C07K2317/56

摘要： The present invention provides humanized, chimeric and human anti-CD20 antibodies and CD20 antibody fusion proteins that bind to a human B cell marker, referred to as CD20, which is useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignancies and autoimmune diseases, and methods of treatment and diagnosis.

公开(公告)号：EP0975674A1

公开(公告)日：2000-02-02

申请号：EP98920171.0

申请日：1998-05-01

申请人： THE GOVERNMENT OF THE UNITED STATES OF AMERICA,as represented by the Secretary,Department of Health and Human Services ,  Immunomedics, Inc.

发明人： RYBAK, Susanna, M. ,  NEWTON, Dianne, L. ,  GOLDENBERG, David, M.

IPC分类号： C07K19/00 ,  A61K47/48

CPC分类号： C07K14/463 ,  A61K38/00 ,  A61K47/6817 ,  A61K47/6849 ,  C07K16/2803 ,  C07K16/2833 ,  C07K16/3061 ,  C07K2319/00

摘要： The present invention relates to immunotoxins, that effectively kill malignant cells having a given surface marker and nucleic acid constructs encoding them. These reagents comprise a toxic moiety that is derived from a Rana pipiens protein having ribonucleolytic activity linked to an antibody capable of specific binding with a chosen tumor cell.

公开(公告)号：EP0778849A1

公开(公告)日：1997-06-18

申请号：EP95928160.0

申请日：1995-08-01

申请人： Immunomedics, Inc.

发明人： GOLDENBERG, David, M.

IPC分类号： G01N33 ,  A61K38 ,  A61K39 ,  A61K47 ,  A61K51 ,  A61P35 ,  C07K16 ,  C12N15 ,  C12P21 ,  C12R1

CPC分类号： B82Y5/00 ,  A61K47/68 ,  A61K47/6898 ,  A61K51/1084 ,  A61K51/1093 ,  A61K2039/505 ,  C07K16/28 ,  C07K16/3007 ,  C07K2317/31

摘要： Polyspecific immunoconjugates and antibody composites that bind a multidrug transporter protein and an antigen associated with a tumor or infectious agent are used to overcome the multidrug resistant phenotype. These immunoconjugates and composites also can be used diagnostically to determine whether the failure of traditional chemotherapy is due to the presence of multidrug resistant tumor cells, multidrug resistant HIV-infected cells or multidrug resistant infectious agents.